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ABSTRACT 
 
The neurotrophic factor GDNF has multiple functions that promote cell survival, proliferation 
and migration in different cell types. The experimental over-expression of GDNF in mouse 
testis leads to infertility and promotes seminomatous germ cell tumors in older animals, which 
suggests that although the underlying mechanisms are unknown, deregulation of the GDNF 
pathway may be implicated in germ cell carcinogenesis. To explore the involvement of the 
GDNF pathway in the onset and progression of testicular germ cell tumors, we firstly 
analyzed the expression pattern of GFRA1 and Ret, the two major co-receptors for GDNF, in 
seminoma samples. We report that GFRA1 was expressed more extensively in carcinoma in 
situ (CIS) cells and intratubular invasive seminoma compared with normal testis.  
Functional analysis of the GDNF biological activity was performed on TCam-2 human 
seminoma cell line. RT-PCR and immunohistochemical analyses demonstrate that TCam-2 
cells express both GFRA1 and Ret mRNA, but only GFRA1 was detected at the protein level. 
It is well known that GDNF plays a central role in spermatogonial stem cell self-renewal and 
proliferation (Hoffman MC et al., 2008). Therefore, in order to evaluate if GDNF could act as 
a mitogenic factor in TCam-2 cells, we performed proliferation assays and cell cycle analyses. 
Interestingly we observed that GDNF doesn’t induce increase in total cell number or S-phase 
entry in TCam-2 cell line. 
Several evidences suggested that GDNF is able to induce cell migration and invasion in 
several normal and tumor cell types (Okada Y et al., 1999; Veit C et al., 2004; Su CM et al., 
2009; Song H et al., 2006; Paratcha G et al., 2006; Tang MJ et al., 1998; Young HM et al., 
2001). Therefore we have hypothesized that GDNF can act as a chemoattractant also in 
seminoma cells. On this purpose we stimulated directional TCam-2 cell migration and 
invasion in the presence of GDNF gradients and we investigated the downstream pathways 
responsible for the GDNF-induced invasive behaviour. We demonstrated that GDNF is able 
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to induce migration, possibly through the Src and MEK pathways. It is documented that 
tumor cell invasion can occur through two modalities: a proteolytic mesenchymal-like or non-
proteolytic amoeboid-like modality (Sahai E and Marshall CJ, 2003; Wolf K et al., 2003). 
GDNF is able to induce TCam-2 seminoma cell invasion in a mesenchymal-like 
metalloprotease-dependent manner. 
In conclusion, GFRA1 over-expression in CIS and seminoma cells, along with the functional 
analyses in TCam-2 cells, suggests an involvement of the GDNF pathway in the progression 
of testicular germ cell cancer. 
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INTRODUCTION 
 
1. Testicular germ cell tumors (TGCTs) 
1.1 Origin and development 
Testicular germ cell tumors (TGCTs) are the most frequent solid malignant tumors among 
young men. Based on epidemiology, clinical presentation, phenotypic characterization, 
chromosomal constitution and genomic imprinting, TGCTs are classified into three groups 
(Oosterhuis JW et al., 2005). Type I comprises the teratomas and yolk-sac tumors of 
newborns and infants (Figure 1); type II comprises the seminomatous and non-seminomatous 
tumors of adolescents and young adults (Figure 1); and type III comprises the spermatocytic 
seminomas of elderly people (Figure 1). During the carcinogenic process, the primordial germ 
cells or gonocytes are converted into a pre-invasive lesion, known as in situ carcinoma (CIS) 
(Kristensen DM et al., 2008; Skakkebaek NE et al., 1972). CIS cells further develop to give 
rise to invasive TGCTs (Figure 2). However, not all TGCTs develop from a CIS, as is the 
case of spermatocytic seminoma of elderly men and infantile germ cell tumors (Kristensen 
DM et al., 2008). 
The fetal origin of CIS cells is not only supported by the morphological similarities among 
CIS cells, primordial germ cells and gonocytes but also by immunohistochemical studies of 
proteins present in all these cell types such as the octamer binding transcription factor 3/4 
(OCT3/4), the placental-like alkaline phosphatase (PLAP), the activating enhancer-binding 
protein 2 gamma (AP-2γ), and the stem cell factor receptor c-KIT (van de Geijn GJM et al., 
2009). Moreover CIS lesions have been identified in prepuberal patients, who later developed 
TGCTs, indicating that these cells originated prior to puberty (Muller J et al., 1984). Thus CIS 
cells are most likely the result of a delayed or blocked differentiation of embryonic germ 
cells. 
i ii
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Fig. 1 – Testicular germ cell tumors (TGCTs).
Hematoxylin & Eosin stained section of: (i) seminoma, (ii) embryonic carcinoma, (iii) yolk-sac tumor, (iv) 
chorioncarcinoma, (v) teratoma and (vi) spermatocytic seminoma. (Modified from Wang P et al., 2010 Am J Clin
Pathol 134:604-612).
 Fig. 2 - Germ cells transformation and tumor progression.  
During the carcinogenic process, primordial germ cells or gonocytes undergo arrest of differentiation and are 
converted into a pre-invasive lesion, known as carcinoma in situ (CIS) (Skakkebaek  et al., 1972, Kristensen  et 
al., 2008). CIS cells further develop to give rise to the invasive testicular germ-cell tumors (TGCTs) of the 
adolescent and young adults, that are seminomatous and non-seminomatous tumors. All these lesions are 
characterized by an up-regulation of germ cell pluripotency genes with an expression pattern more similar to 
embryonic germ cells. However not all TGCTs develop with a CIS, as in the case of spermatocytic seminoma 
of elderly men and infantile germ cell tumors. (From Kristensen DM et al., 2008 Mol.Cell Endocrinol. 288: 
111-118). 
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CIS lesion appears in the form of enlarged cells, usually placed in the basal portion of 
seminiferous tubules, with clear cytoplasm and a round, hyperchromatic nuclei (significantly 
larger than those of spermatogonia) and one or more prominent nucleoli. Supporting its 
neoplastic nature, CIS cells are aneuploid. CIS seminiferous tubules show decreased tubular 
diameter, thickened peritubular basement membrane and absence of normal spermatogenesis. 
Another observation that supports the precursor role of CIS in TGCTs development is that 
CIS cells are found with high frequency in the seminiferous tubules adjacent to invasive germ 
cell tumors. In the absence of an invasive tumor, CIS is asymptomatic and is usually detected 
in testicular biopsies performed for other purposes. About the 50% of the patients with CIS 
lesions develop an invasive TGCT within 5 years from diagnosis and the 70% within 7 years 
(Giwercman A et al., 1993). 
A morphological analysis of parenchyma adjacent to invasive TGCTs suggests that the 
intermediate lesions between CIS and invasive TGCTs are either the intratubular seminoma or 
the intratubular non-seminoma (Oosterhuis JW et al., 2003). During development of 
seminomas, CIS cells become independent from the micro-environment (i.e. the Sertoli cells 
produced factors) and fill up the lumen of the seminiferous tubules. Cell spreading out of the 
seminiferous tubule constitutes the last step for the formation of the overt tumor. Conversely, 
even though non-seminomas are thought to develop from CIS, intratubular non-seminoma is 
invariably composed of pure embryonal carcinoma (EC) and when invasion starts the 
differentiation into its derivatives occurs (teratoma, yolk-sac tumour and chorioncarcinoma) 
(Oosterhuis JW et al., 2005). In this case EC has the ability to differentiate into a wide range 
of cell types and represents the presumed stem cell compartment. EC may undergo down-
regulation of the pluripotency genes and activation of the somatic lineage (Kristensen DM et 
al., 2008). Hence, while seminoma is a uniform tumor resembling early fetal germ cells and 
CIS cells, the more malignant non-seminomas appear heterogeneous and can also contain 
elements of seminoma (Ulbright TM et al., 1999). 
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1.2 Epidemiology and risk factors 
TGCTs account for up to 60% of all malignancies affecting men between 20-40 years of age. 
The rates of TGCTs display geographic and ethnic differences. The incidence of TGCTs in 
Caucasian populations is 6–11/100,000 males but in the last decades an annual increase of 
about 3-6% was registered (Oosterhuis JW and Looijenga LH, 2005). Black populations show 
a lower risk for TGCTs than Caucasians (Moul JW et al., 1994). Moreover high oestrogen 
levels relate with an increased risk of developing a TGCT while high testosterone levels 
reduce the risk. These observations could possibly explain the different incidence rates among 
Caucasians and Blacks (Henderson BE et al.,1988). However, even within the white 
populations, marked differences in the rates of TGCTs development were observed, with 
Denmark detaining the higher incidence. The relatively rapid rise in the incidence of TGCTs 
and the differences among countries and ethinc groups suggest a possible involvement of 
environmental or lifestyle factors in the etiology of these tumors (Rajpert-De ME and Hoei-
Hansen CE, 2007). The importance of this factors is supported by epidemiological studies on 
populations migrating from countries with high incidence (Denmark) and with significantly 
lower incidence (Finland) to Sweden. The first generation immigrants showed the same risk 
of their country of origin, while the second generation, that was born in Sweden, had the same 
incidence of native Swedes (Hemminki K and Li X, 2002). 
In addition, one of the best known risk factor for TGCTs is cryptorchidism, suggesting that 
also the microenvironment plays a crucial role in the regulation of the development of the 
precursor lesion. 
Other risk factors for TGCTs include hypotrophic (<12 ml) or atrophic testicle, Klinefelter’s 
syndrome, familial history of testicular tumours among first-grade relatives, the presence of 
contralateral tumour and infertility (Albers P et al., 2005) but also unspecific factors, such as 
birth order, birth weight and factors related to maternal lifestyle (Rajpert-De ME and Hoei-
Hansen CE, 2007). 
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TGCTs can occur in a sporadic or familial manner. Twin studies showed a greater 
concordance for disease in monozygotic than in dizygotic twins. The segregation analysis 
suggests a recessive mode of inheritance. (Krausz C and Looijenga LH, 2008). 
 
1.3 TGCT gene expression 
In the last decades a significant number of markers has been identified to discriminate CIS, 
seminoma and EC. As previously described, CIS cells share the expression of 
immunohistochemical markers with primordial gem cells and early gonocytes. 
Among the first proteins reported to be expressed both in gonocytes and their malignant 
counterpart there is the stem cell factor receptor KIT (Rajpert-De ME and Skakkebaek NE, 
1994). Together with PLAP is now commonly used as a clinical marker to detect CIS in 
surgical biopsies. 
More recently OCT3/4, a well-characterized marker for primordial germ cells, was discovered 
to be positive in all cases of CIS, seminoma and derived invasive cancers (Looijenga LH et 
al., 2003; Rajpert Rajpert-De ME et al., 2004). OCT3/4 is a transcription factor of the family 
of the octamer-binding proteins and is a well known key regulator of pluripotency, (de Jong J 
and Looijenga LH, 2006). Another important gene known for its association with 
pluripotency in embryonal stem (ES) cells is the homeobox proteing NANOG. Similarly to 
OCT3/4, NANOG is expressed not only in CIS cells but also in the overt germ cell tumor 
(Hoei-Hansen CE et al., 2005). 
Among the novel markers for TGCT there is AP-2γ, another transcription factor associated 
with the undifferentiated state and suggested as a possible marker for CIS in semen specimen 
of patient with early stages of TGCT (Hoei-Hansen CE et al., 2007). 
All these stem cell-related proteins are physiologically abundantly expressed in fetal pre-
meiotic germ cells of both sexes. At the onset of meiotic prophase their expression is 
normally rapidly down-regulated (Rajpert-De ME and Hoei-Hansen CE, 2007).  
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However, among the histological types of CIS-derived invasive tumors, marked differences in 
the expression of embryonic genes were observed (Kristensen DM et al., 2008). While 
seminoma phenotype is closely similar to CIS, the EC (the undifferentiated stem cell 
compartment of non-seminomas) is strikingly related to that of ES cells, suggesting a re-
programming or a differentiation event. For example, the SRY (sex determining region Y)-
box 2 (SOX-2) is highly expressed in non-seminomas, whereas seminomas are negative for 
this marker (Sperger JM et al., 2003; Santagata S et al., 2007). Accordingly SOX2 belong to 
the SOX protein family of transcription factors that regulate the development from the early 
embryonal stage to specific lineages (Avilion AA et al., 2003, Tay Y et al., 2008). 
 
1.4 Genomic aberrations 
CIS, seminomas, and all variants of nonseminomas are aneuploid, as demonstrated by flow 
cytometry as well as cytogenetic approaches. (Oosterhuis JW et al., 1989; Murty VV et al., 
1990; De Graaff WE et al., 1992; Van Echten-Arends J et al., 1995). Even if altered copy 
number of regions on chromosome 7, 8, 14, 17 and X have also been consistently reported 
(Looijenga LHJ et al., 2000; Summersgill B et al.,2001; Ottesen AM et al., 2003; Ottesen AM 
et al., 2004), the main recurrent structural imbalance in these tumors is the gain of the short 
arm of chromosome 12, mostly in the form of an isochromosome (Looijenga LHJ et al., 
2003). At which stage during tumour development genomic instability is introduced is 
uncertain (Skotheim RI and Lothe RA, 2003). However the observation that gain of 12p 
material is detected in CIS cells near the overt tumours (Ottesen AM et al., 2003) suggests 
that this event is related to the invasive growth of the type II TGCTs (Rosenberg C et al., 
2000; Summersgill B et al., 2001). Interestingly, gain of 12p region is also found in in vitro 
cultured human ES cells, suggesting a relation with an improved capability to survive in a 
non-physiological environment (Draper JS et al., 2003; Li SS et al., 2006). 
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One of the genes located on 12p region that could play a relevant role in favoring TGCTs 
progressions is the cyclin D2 (CNND2). This gene is indeed overexpressed in type II TGCTs 
and CIS (Houldsworth J et al., 1997; Kukoski R et al., 2003). However, this region contains 
also other genes associated with pluripotency and proliferation, including the small GTPase 
K-RAS and NANOG, that has been suggested to be relevant in invasive TGCTs progression, 
although the actual proof is lacking so far (Krausz C and Looijenga LH, 2008). 
 
1.5 TCam-2 cell line 
Currently, various non-seminomatous cell lines have been established, but only one (i.e. 
TCam-2) (de Jong J et al., 2008; Eckert D et al., 2008; Goddard NC et al., 2007; Mizuno Y et 
al., 1993) has been established from seminoma, although they constitute more than 50% of all 
TGCTs. This is probably due to the capability of seminoma cells to undergo to rapid 
apoptosis after disruption of their microenvironment (Olie RA et al., 1996). TCam-2 cell line 
originated from a primary testicular seminoma of a 35-year-old patient (Mizuno Y et al., 
1993). The initial in vitro culture was subcloned after 15 passages, and after 18 passages the 
cells were also successfully transplanted into the back of CB-17 SCID mice. Electron 
microscopy demonstrated the presence of significant amounts of glycogen and absence of 
intercellular connection structures. Karyotyping after 10 passages in vitro showed 90–96 
chromosomes, including the lack of the Y chromosome (Mizuno Y et al., 1993). 
TCam-2 cells display the characteristic gain of chromosome 12p, a chromosomal aberration 
common to all the invasive germ cell tumors but not spermatocytic seminoma (De Jong J et 
al., 2008). Original cytogenetic analysis using Giemsa banding identified five copies of 
chromosome 12 (Mizuno Y et al., 1993). Successively Goddard and coworkers identified by 
metaphase and interphase fluorescence in situ hybridization analysis further four copies of the 
12 centromere and material from the 12p11.2-12.1 region but no isochromosome of 12p 
(Goddard NC et al., 2007). No expression of alpha fetal protein (αFP) or beta-human 
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choriogonadotrophin (βhCG), respectively markers for yolk-sac tumors and 
chorioncarcinoma, was described, while strong staining for the seminoma marker PLAP has 
been reported (Mizuno Y et al., 1993). As in the case of seminoma, the pluripotency genes 
Oct3/4 and Nanog are highly expressed in TCam-2 cells as detected by 
immunohistochemistry and western blot analysis (Goddard NC et al., 2007; De Jong J et al., 
2008). Instead the embryonic stem cell marker SOX2, typically highly expressed in EC but 
absent in seminomas, is not expressed in TCam-2 cells both on protein and mRNA level (De 
Jong J et al., 2008). The transcription factor AP-2γ, a known specific marker used for 
diagnosis of seminomas, was expressed as revealed by RT-PCR, western blot analysis and 
immuhistochemistry (Eckert D et al., 2008). In addition, the tumor necrosis factor receptor 
superfamily member 8 (CD30) usually expressed in EC and EC-derived cell lines and related 
to inhibition of apoptosis, is not expressed in TCam-2 cells on protein level nor on mRNA 
level (de Jong J et al., 2008).  
Moreover, the stem cell factor (SCF) receptor, KIT, and its ligand SCF were both expressed 
in the TCam-2 cells as determined by immunoprecipitation for KIT (de Jong J et al., 2008, 
Goddard NC et al., 2007), western blot analysis and immuhistochemistry (Eckert D et al., 
2008). KIT mutations have been described in bilateral TGCTs (Looijenga LH et al., 2003) but 
sequencing analysis of exons 9, 11, 13 and 17 did not detect any activating mutations of KIT 
in TCam-2 cells (Goddard NC et al., 2007). Finally, the expression of the typical germ cell 
markers VASA (ATP-dependent RNA helicase), DAZL (DAZ (deleted in azoospermia) 
ligand) and BOULE (another member of the human DAZ gene family) were observed (Eckert 
D et al., 2008). 
Unlike other solid tumors, type II TGCTs have a low mutation rate in protooncogenes, 
including BRAF and KRAS2 (Sommerer F et al., 2005), as well as the tumor suppressor gene 
TP53 (Kersemaekers AM et al., 2002). Mutation analysis of these genes in TCam-2 cells 
showed a mutation in the protooncogene BRAF, due a thymine to adenine transversion at 
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nucleotide 1796 (T1796A), leading to a substitution of glutamic acid for valine at amino acid 
600 (V600E) (de Jong J et al., 2008). It has been suggested that this mutation could be the 
explanation for the successful propagation of these cells in vitro. Because of the lack of the 
primary tumor, it is not possible to determine whether this mutation was present in the 
original tumor, or was generated due to in vitro propagation (de Jong J et al., 2008). On the 
other hand, recently Goddard and coworkers, described that the TCam-2 cell line does not 
show evidence for a V600E BRAF mutation (Goddard NC et al., 2010). These authors 
performed direct sequencing of both the forward and reverse strands of the BRAF gene in 
TCam-2 cells and normal female DNA revealing that the sequence is wildtype at nucleotide 
1796. They hypothesized that the mutation detected by de Jong J and coworkers (de Jong J et 
al., 2008) could be present only in a small subpopulation of TCam-2 or alternatively, a BRAF 
mutation may have arisen independently or the mutant allele may have been lost during 
prolonged culture in different laboratories. In conclusion they affirmed that the BRAF 
mutation can not account for the establishing of TCam-2 cell line from a seminoma sample. In 
their opinion rather other factors, including mutations in other genes or the overexpression of 
receptors or growth factors, may account for their in vitro growth (de Jong J et al., 2008).  
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2. Tumor tissue invasion and metastasis 
2.1 Mesenchymal and amoeboid cell invasion 
Cell migration plays a key role in metastatic dissemination of tumour cells from the primary 
tumour to local and distant sites (McSherry EA et al., 2007; Farrow B et al., 2008; Condeelis 
J and Segall JE, 2003). 
Even if tumour cells in vivo can move both randomly and directionally, invasion is more 
efficient when the cell is involved in directed migration toward a chemokine gradient 
(chemotaxis) (Roussos ET et al., 2011). Thus, chemotaxis is on the base of several major 
events during tumour progression: metastatic invasion and dissemination, angiogenesis and 
immune cell extravasation (Roussos ET et al., 2011). 
Different modes of invasive migration have been described for cancer cells: amoeboid 
migration or mesenchymal migration for single cells and collective migration of groups of 
cells (Roussos ET et al., 2011). Amoeboid cell motility of single tumour cells is independent 
from the activity of matrix metalloproteinases (MMPs) because cells can infiltrate through 
gaps in the extracellular matrix (ECM) because their cytoskeleton contractile capability (Wolf 
K. et al., 2003; Wyckoff JB et al., 2006). Intravital multiphoton imaging had permitted to 
observe migrating cells in vivo revealing that some carcinoma cells with an amoeboid 
morphology can move at high speeds inside the tumours (~4 µm min–1) (Condeelis J and 
Segall JE, 2003). On the other end, mesenchymal migration that typically involve single cells 
but sometimes also collective migration, is characterized by polarized cells with an elongated 
cell morphology and relatively low speeds of cell migration (0.1–1 µm min–1) (Sahai E, 
2005). However, even if amoeboid and mesenchymal modes of migration can be observed as 
separated mechanisms by in vitro studies, evidence suggests that in vivo they can convert into 
each other in response to changes in the microenvironment (Sahai E and Marshall C, 2003; 
Pankova K et al., 2009). For example, a transition from mesenchymal to amoeboid tumor cell 
migration can be induced by inhibition of proteolysis (Wolf K et al., 2003). 
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Collective migration has been defined as the coordinate movement through the ECM of 
clusters or sheets of tumour cells with functionally intact cell–cell adhesions (Friedl P and 
Gilmour D, 2009). The leader cells positioned at the front of the migrating group actively 
migrate toward a chemotactic gradient creating a track by matrix degradation (Rorth P, 2007; 
Ilina O and Friedl P, 2009; Valentin G et al., 2007; Schmidt M et al., 2007; Aman A and 
Piotrowski T, 2008). The other cells follow the leader cells along the remodeled matrix tracks 
due to the physical coupling that generate drag forces (Rorth P, 2007). The leader cell can be 
either a tumour cell with proteolytic activity or a stromal cell from the tumour 
microenvironment (Gaggioli C et al., 2007; Rorth P, 2007; Wolf K, 2007). 
The occurrence and frequency of these modes of migration in cancer is dependent on tumor 
cell types and tumour microenvironment.  
Despite the various patterns of directed migration during tumour cell dissemination, the 
intracellular processes involved in cell motility are probably similar and are comprised of 
three main steps: chemo-sensing, polarization and locomotion (Iglesias PA, Devreotes PN, 
2008). First, polarized intracellular signals lead to asymmetric actin polymerization resulting 
in extension of the cell membrane in the direction of movement, thus creating the leading-
edge protrusion. This is followed by integrin-mediated adhesion to the substrate in the 
direction of movement, and by subsequent detachment from the substrate on the opposite side 
after contraction of the trailing edge of the cell (Figure 3). Nodal point for regulation of these 
migratory processes are the small GTPases such as Rho, cdc42, and Rac (Gupta GP and 
Massague J, 2006) 
 
2.2 Contributions of stromal cells to invasion and metastasis 
Cancer cells typically produce mediators that induce chemotactic recruitment and activation 
of a variety of cell types into the surrounding stroma (such as fibroblasts, myofibroblasts, 
granulocytes, macrophages, mesenchymal stem cells, and lymphocytes) which contribute to 
 Fig. 3 - Schematic representation illustrating the different phases of cell migration.  
Polarized intracellular signals lead to asymmetric actin polymerization resulting in extension of the cell 
membrane in the direction of movement, creating the leading-edge protrusion. This event is followed by 
integrin-mediated cell-substrate adhesion (focal contacts) in the direction of movement, and by subsequent 
detachment on the opposite side after contraction of the trailing edge of the cell. (From Molecular Biology of 
the Cell; Alberts). 
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the formation of an inflammatory microenvironment (Gupta GP and Massagué J 2006). 
Therefore, invasion occurs in a restricted zone of cross-talk and cooperation between this 
“reactive” stroma and the premalignant epithelium (Figure 4).  
The proteolytic machinery of the activated stromal cells, combined with that of tumor cells, 
degrades extracellular matrix (ECM) proteins, uncovering cryptic sites that may display pro-
migratory properties and releasing sequestered growth and survival factors (Liotta LA and 
Kohn EC, 2001).  
In this scenario, invasive carcinoma may be viewed as “a pathology of multiple cell societies 
inhabiting the epithelial/mesenchymal stromal unit” (Liotta LA and Kohn EC, 2001). Thus, 
tumor cells could convert reactive stromal infiltrates from preservers of tissue homeostasis 
into accomplices in malignancy. Accordingly, leukocytic infiltration, angiogenesis, and 
lymphangiogenesis, all markers for stromal cells and tumor coexistence, are frequently 
correlated with an increased likelihood of metastatic relapse (Gupta GP and Massagué J, 
2006). However the stromal reaction to invading tumor cells is variable, depending in part 
upon tumor cell properties and in part upon the local stromal composition (Bacac M and 
Stamenkovic I, 2008).  
During the biological cascade of metastasis, a cancer cell from a primary tumor executes 
several discrete steps: i) emigration from the primary tumor and invasion of the surrounding 
tissue and degradation of ECM; ii) intravasation into the microvasculature of blood or 
lymphatic system iii) survival and translocation largely through the bloodstream and lymph to 
microvessels of distant tissues and finally iv) extravasation and v) metastasis formation at 
target tissues (Figure 5). Since cancer cells exit from the bloodstream, they have to adapt to 
the foreign microenvironment to survive and give rise to a macroscopic secondary tumor 
(colonization) (Fidler IJ et al., 2003).  
 Fig. 4 – Stromal reaction. 
Advanced malignancies are frequently coinhabited by different stromal cell types. The tumor-suppressive 
activities of lymphocytes (T, B, and NK cells) is in part antagonized through the release of immunosuppressive 
cytokines. Carcinoma-associated fibroblasts (CAFs) can secrete factors that promote both tumor cell growth and 
invasion and neoangiogenesis (through recruitment of bone marrow dendritic cells (BMDC) from circulation). 
Activated macrophages were recruited to tumors and can release many pro-tumorigenic growth factors. 
Additionally, macrophages may co-migrate with cancer cells within tumors through a paracrine growth-factor 
loop. Once cancer cells have invaded the blood stream, many of them will die from stresses associated with 
circulatory passage. The remaining survivors may attach to capillaries within a secondary organ through 
adhesion receptors. Subsequently, cancer cells can extravasate from capillaries and may or may not generate a 
viable niche at the secondary site.(From Gupta GP and Massagué J, 2006 Cell 127: 679-695). 
 Fig. 5 - The metastatic cascade.  
Metastasic process can be subdivided in two major phases: (i) physical translocation of cancer cells from the 
primary tumor to a distant organ and (ii) colonization of the translocated cells within that organ. (A) To begin 
the metastatic cascade, cancer cells within the primary tumor acquire an invasive phenotype. (B) Cancer cells 
can then invade into the surrounding matrix and toward blood vessels, where they intravasate to enter the 
circulation, which serves as their primary means of passage to distant organs. (C) Cancer cells traveling through 
the circulation are referred as circulating tumor cells (CTCs). (D) At the distant organ, CTCs exit the circulation 
and invade into the microenvironment of the foreign tissue. (E) At that foreign site, cancer cells must be able to 
evade the innate immune response and also survive as a single cell (or as a small cluster of cells). (F) To 
develop into an active macrometastatic deposit, the cancer cell must be able to adapt to the microenvironment 
and initiate proliferation. (From Chaffer CL and Weinberg RA, 2011 Science 331, 1559). 
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3. TGCTs and seminoma invasion 
Although the cure rate for TGCT is high, presence of metastases reduces survival rates. 
Interestingly, metastasis is a prevalent feature of human TGCTs showing a very high number 
of metastases compared with other tumours, averaging 5.8 metastases per primary tumour (De 
Giorgi U et al., 2008). Approximately 30% of patients affected by TGCTs presents metastases 
at the time of diagnosis (Powles TB et al., 2005), and 15–20% of patients have subclinical 
metastases in stage I seminoma (Benne R et al., 1986), the most common presentation among 
TGCTs. While tumors remain confined to the testis in about 75% of patients, a retroperitoneal 
involvement is observed in the 20%, and the remaining 5% shows supradiaphragmatic or 
organ metastases (Ulbright TM et al., 2009). 
Therefore metastases represent important factors directly affecting treatment modality, 
tumour surveillance, and survival (Zechel JL et al., 2011). Treatment for TGCTs involves 
surgery and chemotherapy with bleomycin, etoposide and cisplatin (BEP), obtaining a relative 
low mortality risk of 2.3–4.5% (Fossa SD et al., 1998; Williams SD et al., 1987). Although 
many TGCTs and their metastases respond readily, 10–25% of patients with metastases are 
resistant to chemotherapy (Piulats JM et al., 2009), further complicating treatment and 
worsening prognosis. Moreover, patients with a metastatic disease suffer frequently of a 
higher incidence of relapse (5–10%) after treatment (Lutke Holzik MF et al., 2008) and a 
lower survival rate (Loehrer PJ et al., 1998). 
Even though the clinical and epidemiological aspects of TGCTs are well described, very scant 
informations are available about the molecular mechanisms for tumor spreading and 
metastasis. Testicular cancer metastases exhibit a conserved pattern targeting various tissues, 
such as lymph nodes, lung, liver, bone and spleen (De Giorgi U et al., 2008).  
It has been observed that this TGCT pattern of metastases abundantly overlap with that of 
CXCL12 expression. In fact, metastases target organs that express high levels of the 
chemokine CXCL12 (SDF-1), resembling patterns observed in other CXCR4 over-expressing 
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cancers (breast, colorectal and prostate cancers) (Gilbert DC et al., 2009). In normal human 
testes, CXCL12 is expressed by Sertoli cells and its receptor CXCR4 by the germ cell 
population. CXCL12 is able to stimulate invasive cell migration of TCam-2 seminoma cell 
line in a CXCR4-dependent fashion via activation of ERK. More interestingly high-level 
CXCL12 expression in tumors correlates with reduced risk of TGCT occult metastases and 
relapse after surgical treatment (Gilbert DC et al., 2009). 
Even if seminoma is generally pain-less, about 2,5% of patients presenting a metastatic 
involvement suffers most commonly of lumbar pain due to retroperitoneal metastasis, even if 
gastroinstestinal bleeding, bone pain, dyspnea and cough, a supraclavicular mass, 
neurological symptoms, and lower extremity edema may also be presenting symptoms due to 
spread to other sites. Such metastases, however, can be asymptomatic (Ulbright TM et al., 
1999). 
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4. Glial derived neurotrophic factor (GDNF) 
4.1 GDNF and co-receptors 
GDNF is a distant member of the transforming growth factor beta (TGF-β) superfamily (Lin 
LF et al., 1993). GDNF was first identified through its activity on midbrain dopaminergic 
neurons but subsequently, it has been shown to have pleiotropic functions, promoting 
neuroprotection, cell proliferation, and migration (Sariola H and Saarma M, 2003).  
Mice lacking GDNF die within the first day of birth due to severe defects in renal 
differentiation and the absence of an enteric nervous system (Moore MW et al., 1996; Pichel 
JG et al., 1996; Sanchez MP et al., 1996). The animals lacking GDNF receptors show the 
same phenotypes, indicating that GDNF pathway is essential for postnatal survival in the 
mouse (Schuchardt A et al., 1994; Enomoto H et al., 1998; Cacalano G et al., 1998).  
GNDF, along with the other members of the GDNF family of neurotrophic factors (neurturin, 
artemin and persephin), is a basic, dimeric, secretory protein. GDNF is first synthesized as an 
inactive 211 amino acids long preproGDNF. Subsequently the secreted proGDNF is 
proteolytically cleaved to form the mature GDNF protein of 134 amino acids (Saarma M and 
Sariola H, 1999). The specific proteases that cleave and activate GDNF precursors have not 
yet been identified. The GDNF mature protein is N-glycosylated at two amino acid residues, 
even if the role of these carbohydrates in the biological activity of GDNF has not yet been 
established (Lin LF et al., 1993). Moreover GDNF contains seven cysteine residues in the 
same relative spacing as in the members of the TGF-b superfamily. Although the amino acid 
sequence homology between the GDNF and the TGF-b superfamily is less than 20%, the 
pattern of cysteine residues makes GDNF a distant member of this family (Lin LF et al., 
1993). According to the crystal structure, the GDNF monomer forms two finger-like (Finger 1 
and Finger 2) structures by pairs of antiparallel β-strands with a α-helix at the opposite end 
(Eigenbrot C and Geber N, 1997). The GDNF homodimer is formed by head-to-tail 
dimerization, which is supported by one interchain disulphide bond among the unpaired 
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cysteines in monomers that are not part of the cysteine knot. Only the homodimer of GDNF is 
biologically active (Saarma M and Sariola H, 1999). 
GDNF exerts its effect on target cells by binding to a glycosyl phosphatidylinositol–linked 
GDNF family receptor-a 1 (GFRA1); this binding recruits the tyrosine kinase receptor Ret to 
form a multi-subunit signaling complex of GDNF/GFRA1/Ret.  
While the other members of TGF-b superfamily signal through transmembrane serine-
threonine kinase receptors, the GDNF receptor Ret is a typical tyrosine kinase receptor. Ret is 
a single-pass transmembrane protein that contains four cadherin-like repeats in the 
extracellular domain (607 amino acids), a cysteine rich domain, a hydrophobic 
transmembrane region and a cytoplasmic intracellular part with a kinase domain (Anders J et 
al., 2001; Iwamoto T et al., 1993; Kuma K et al., 1993). Moreover a Ca2+-binding site is 
localized between cadherin-like domain 2 and 3 (Anders 2001). 
The GPI-anchored receptor GFRA1 contains a N-terminal hydrophobic domain codifying for 
the secretory signal sequence and a C-terminal sequence with 23 hydrophobic amino acids. A 
group of three small amino acids proceeding the stretch of hydrophobic amino acids indicates 
a possible GPI-binding/cleavage site (Undenfriend S and Kodukula K, 1995). 
GFRA1, as most GPI-linked proteins, can be localized to specialized detergent-resistant 
membrane fractions, named lipid rafts. These structures are described as floating membrane 
platforms in the exoplasmic leaflet of the membrane bilayer enriched in cholesterol and 
sphingolipids (Simons K and Ikonen E, 1997). Several protein families have high affinity for 
lipid rafts, such as Src-family kinases and small GTP-ases, making them signaling platforms 
for various transmembrane and GPI-linked proteins (Saarma M, 2001; Simons K and Toomre 
D, 2000). 
The original model described the GDNF/GFRA1 binding and activation of Ret receptor as an 
in cis interaction between two receptors expressed on the same cell (Jing S et al., 1996). This 
model is supported by the overlapping expression of Ret receptor and GFRA1 in the same cell 
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population (Golden JP et al., 1998; Tansey MG et al., 2000). However also another 
mechanism has been reported where the GFRA1 receptor can be released from the cell 
surface by cleavage of the GPI-anchor and acts as a soluble receptor. According to this in 
trans model, the soluble GFRA1 molecule presents the ligand to Ret located in the membrane 
of another cell (Figure 6). It has been suggested that the in trans signaling can sustain and 
increase the response achieved through the canonical in cis pathway (Paratcha G et al., 2001). 
In this last case, GDNF binds to the GPI-linked GFRA1 receptor into lipids rafts, recruiting 
Ret in this compartment which binds and activates the lipid-anchored adaptor protein FRS2 
(fibroblast growth factor receptor substrate 2). During the in trans activation, instead, GDNF 
binds to soluble GFRA1 and this complex binds and activates Ret on neighboring cells 
outside the lipid rafts. The activated receptor associates with and phosporylates SHC (Src-
homologous and collagen-like protein) (Paratcha G et al., 2001; Airaksinen MS and Saarma 
M, 2002). 
Once GDNF/GFRA1 complex binds to Ret, two transmembrane Ret molecules dimerize and 
transphosporylate cytoplasmic tyrosines, triggering several cell signaling cascades 
(Airaksinen MS and Saarma M, 2002). 
 
4.2 GDNF transduction pathways 
The GDNF-GFRA1 binding to Ret extracellular domain leads to Ret autophosphorylation at 
many tyrosine residues on its intracellular domain (Airaksinen MS and Saarma M, 2002). The 
phosphorylated tyrosine residues of activated Ret act as docking sites for various adaptor 
proteins that in turn may activate different pathways in target cells (Airaksinen MS and 
Saarma M, 2002). 
For instance, the Src signaling pathway, activated by Ret Tyrosine 981 phosphorilation, elicits 
neurite outgrowth, neuronal survival and ureteric branching (Airaksinen MS and Saarma M, 
2002) as well as spermatogonial stem cells (SSCs) self-renewal and proliferation in mouse 
  
Fig. 6 - GDNF receptor complex signaling.  
In cis pathway (left): GDNF binds to GPI-anchored GFRa1 receptors in lipid rafts (1), resulting in the 
recruitment and activation of c-Ret in this compartment (2). c-Ret associates with and activates FRS2 inside 
and SHC outside lipid rafts. Activated c-Ret is in equilibrium between raft and non-raft compartments (3). 
During activation in trans (right), a complex of GDNF and soluble GFRa1 (sGFRa1) released from 
neighbouring cells binds to and activates c-Ret outside rafts (1), where the activated receptor associates with 
and phosphorylates SHC. c-Ret is then recruited to rafts by a mechanism dependent on its tyrosine kinase 
activity and phosphorylation of Tyr-1062 (2). Inside lipid rafts, c-Ret associates with and activates FRS2. Both 
c-Ret and GFRa1 are believed to function as homodimers; however, for simplicity, only monomers are 
represented in this cartoon. (From Paratcha G et al., 2001 Neuron 29: 171–184). 
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testes (Hoffman MC, 2008). Four Src family kinases have been so far implicated in the Ret 
mediated SSCs proliferation: Src, Yes, Lyn and Fyn. Further Src activates the PI3K/Akt 
signaling pathway leading to N-myc expression and promoting SSCs self-renewal (Hoffman 
MC, 2008). 
Another important transduction pathway activated by GDNF/GFRA1/Ret complex is the Ras 
signaling pathway. In the developing enteric nervous system, the developing kidney, and in 
neuroblastoma it is triggered by Ret Tyr 1062 phosphorylation (Worby CA et al., 1996; Jijiwa 
M et al., 2004; Hayashi H et al., 2000).  
Concerning SSCs, instead, the rapid and transient activation of the Ras/ERK1/2 pathway was 
induced by GDNF binding and activation of the protein adaptors Shc and Grb2. At the end of 
this signaling cascade, some transcription factors such as Creb-1, Atf-1, and Crem-1 were 
phosphorilated and therefore activated. Finally, the Gdnf/Ret/Ras axis up-regulates the 
transcription levels of the immediate-early gene c-fos, the cell cycle activator cyclin A, as 
well as Cdk2 (Hoffman MC, 2008). Cyclin A is a key regulatory protein of the cell cycle S-
phase entry and associates with Cdk2 in mammalian cells (Cardoso MC et al., 1993). 
Therefore, like in other cell types, Creb and c-Fos enhance the expression of cyclin A and 
favor the G1/S cell cycle transition in GFRA-positive spermatogonia (Desdouets C et al., 
1995; Sunters A et al., 2004). 
 
4.2.1 Ret-indipendent transduction pathways  
Recently, some observations suggest that the GDNF/GFRA1 complex can transduce also in a 
Ret-independent fashion (Sariola H and Saarma M, 2003). In support of this hypothesis, the 
GFRA1 expression is widespread in many areas of the nervous system, and especially in the 
forebrain, cortex and inner ear where no expression of Ret is detected (Trupp M et al., 1997; 
Kokaia Z et al., 1999). 
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In RET deficient cell lines and primary neurons, GDNF is able to trigger Src family kinase 
activation and phosphorylation of the ERK/MAP kinase, the phospholipase C-gamma (PLC-
γ) and the nuclear transcription factor cAMP Responsive Element Binding Protein (CREB), 
and induction of the protoncogene Fos (Poteryaev D et al., 1999; Trupp M et al., 1999). In 
RET-deficient mice exhibiting severe renal hypodysplasia, GDNF partially restores ureteric 
branching morphogenesis (Popsueva A et al., 2003). In MDCK cells expressing GFRA1 but 
not RET, GDNF stimulates branching but not chemotactic migration (Sariola H and Saarma 
M, 2003). In several RET-deficient but GFRA1-positive cells GDNF induces Met 
phosphorylation suggesting a contribute of Met to RET-independent GDNF signaling (Sariola 
H and Saarma M, 2003). However, since GDNF does not immunoprecipitate Met, a direct 
interaction between GDNF and Met seems improbable. Instead the GDNF-triggered RET-
independent Src and Met activation might be mediated by neural cell adhesion molecule 
(NCAM). Ibañéz C. and co-workers investigated the Ret-indipendent GDNF signaling 
mechanisms in the immortalized neuronal precursors RN33B and in primary Schwann cells, 
which are reported to express relatively high levels of GFRA1, but no Ret receptor. They 
observed that, in the absence of GFRA1, GDNF interacts with NCAM with low affinity 
(Paratcha G et al., 2003). When GFRA1 is associated with NCAM, instead, GDNF binds with 
high affinity to p140NCAM and activates Fyn and focal adhesion kinase (FAK) in the 
cytoplasm (Paratcha G et al., 2003). According to these observations, GDNF effects on 
midbrain dopaminergic neurons in vitro and in vivo are inhibited by an NCAM blocking 
antibody, giving support to the physiological relevance of GDNF signaling through NCAM 
(Chao CC et al., 2003). 
 
4.3 GDNF and spermatogenesis  
In rodent testis, GDNF is produced by the Sertoli cells, the somatic cells supporting germ cell 
development (Tadokoro Y et al., 2002). However, in human testis, GDNF is produced by 
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Sertoli cells and by cells of the peritubular wall of the seminiferous tubules (Spinnler K et al., 
2010). GDNF is important for male fertility because it plays a central role in spermatogonial 
stem cell self-renewal and proliferation (Hofmann MC et al., 2008). Reduced GDNF dosage 
in heterozygous GDNF+/- animals leads to an excessive differentiation of spermatogonia and 
finally to an exclusive Sertoli-cell-only phenotype, whereas over-expression of GDNF leads 
to a block of stem cell differentiation (Meng X et al., 2000) (Figure 7).  
Although mice lacking GDNF or its receptors GFRA1 and Ret die within the first day of 
birth, due to severe defects in renal differentiation and the absence of an enteric nervous 
system (Moore MW et al., 1996; Pichel JG et al., 1996; Sanchez MP et al., 1996), the 
testicular morphology of these mice is normal before birth.  
Transplantation of GDNF, GFRΑ-1 and Ret deficient neonatal testes under the back skin of 
immunodeficient mice to monitor the development of the grafted testes revealed that any 
disruption of GDNF-mediated Ret signaling results in a lack of SSCs self-renewal and 
induces the progressive loss of spermatogenesis by germ cell depletion (Naughton CK et al., 
2006). On the contrary, normal spermatogenesis was observed in the grafted wild-type testes. 
In the last decade, GDNF has been described as an essential factor in the maintenance and 
expansion of in vitro SSCs in different mammals (Kanatsu-Shinohara M et al., 2003; 
Kanatsu-Shinohara M et al., 2008; Kubota H et al., 2004; Wu Z et al., 2009). Microarray 
analysis on in vitro cultured SSCs showed that GDNF administration induces the upregulation 
of some transcription factor-encoding genes, including Bcl6b, Etv5 and Lhx1 and interestingly 
of Gfra1 (Oatley JM et al., 2006). In order to determine whether these GDNF-induced 
transcription factors are relevant to SSCs functions, their expression was transiently reduced 
by RNA interference in cultured mouse SSCs. After cell transplantation in recipient mouse 
testes, it has been observed that SSCs expansion in vitro was impaired, suggesting that 
BCL6B, ETV5 and LHX1 are important factors for SSCs self-renewal (Oatley et JM al., 
2006; Oatley JM et al., 2007). 
 GDNF dosage 
Fig. 7- GDNF dosage rule the correct balance between stem cell self-renewal and differentiation.  
When GDNF level is low, the sprematogonial stem cells undergo differentiation while high GDNF dosage 
induces stem cell self-renewal. Transgenic mice with loss or gain of function of Gdnf show disturbed 
spermatogenesis. (Modified from Sariola and Saarma, 2003 J. Cell. Sci. 116: 38-59). 
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The GDNF receptor GFRA1 has been found to be expressed by SSCs isolated from immature 
mouse testes (Buageaw A et al., 2005) but not by SSCs from cryptorchid adult testes (Ebata 
KT et al., 2005; Orwig KE et al., 2008). According to dependence of SSCs self-renewal in in 
vitro culture upon GDNF administration, GFRA1 expression is maintained by cultured SSCs.  
However both rodent and human SSCs do not uniformly express GFRA1 (Grisanti L et al., 
2009). In particular, in humans, where SSCs are among Adark (Ad) and Apale (Ap) 
spermatogonia (De Rooij DG and Russell LD, 2000), only a fraction of the Ad and Ap 
spermatogonia expresses GFRA1 (Grisanti L et al., 2009). In the same year, the Schlatt’s 
group published a related paper about GFRA1 expression in human SSCs. Four distinct 
subpopulations of GFRa1-positive cells were observed which could be distinguished 
according to differences in the cell sizes and additional morphological criteria (Gassei K et 
al.,  2010). 
In the testis, the regulation of GDNF expression is still poorly understood. However the 
GDNF production by Sertoli cells is known to be dependent on the follicle-stimulating 
hormone (FSH) (Tadokoro Y et al., 2002). In order to study the GDNF/FSH pathway, male 
Sl/Sld mutant mice, whose testes produce only undifferentiated type A spermatogonia, were 
used. FSH stimulation mediated by Sertoli cells was abolished by injecting a gonadotropin 
releasing hormone antagonist (Nal-Glu) resulting in a decrease of GDNF production and 
undifferentiated spermatogonia proliferation. Moreover primary cultures of Sertoli cells 
respond to FSH increasing the GDNF production. This observation was also confirmed by 
Simon and colleagues, who demonstrated that FSH increases the GDNF level expression in 
the Sertoli cell line TM4 (Simon L et al., 2007). In addition, they observed that the GDNF 
production by primary Sertoli cells in vitro is dependent on fibroblast growth factor 2 (FGF2), 
tumor necrosis factor alpha (TNF-α) and interleukin-1beta (Il-1β) (Simon L et al., 2007). 
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4.4 GDNF and cancer 
Even though physiological functions of GDNF in normal cells and tissues are well 
documented, less is known concerning the role of GDNF in cancer. GDNF promotes cell 
migration/chemotaxis and invasion of human pancreatic (Okada Y et al., 1999; Veit C et al., 
2004), chondrosarcoma (Su CM et al., 2009) and glioma cell lines (Song H et al., 2006). 
Interestingly, older transgenic mice that over-express GDNF frequently develop testicular 
tumors with the morphology and immunohistochemical profile (placental-like alkaline 
phosphatase positive) of classical human seminomas (Meng X et al., 2001). The GDNF 
transgene has been expressed in testes under the translation elongation factor 1α promoter. All 
male GDNF overexpressing mice are infertile and after two weeks of age start to accumulate 
undifferentiated spermatogonia which form large cell clusters occluding seminiferous tubules. 
Around ten weeks of age, these clusters undergo apoptosis with subsequent testis atrophy. 
However a rim of spermatogonia still remains in the periphery of the tubules. Invasion of 
undifferentiating spermatogonia into the interstitium occurs after a year of age (Meng X et al., 
2000) and 89 percent of mice develops testicular tumors. No distant metastases were found by 
autopsy or histological analysis (Meng X et al., 2001). 
Even if the murine seminomatous tumors resemble human seminomas for many aspects, some 
differences are also been observed. Firstly, in most transgenic mice tumors developed 
bilaterally (56%), while in humans they were mainly unilateral. Secondly, whereas distorted 
spermatogenesis was detected in mouse, a normal spermatogenetic process was maintained in 
man. Moreover, tumors appeared at old age in mouse and at young age in man. Finally, the 
large lymphocyte infiltrate present in most of human seminomas is absent in mouse tumors. 
However, in spite of these differences, at the present time this is the only available animal 
model for seminoma (Meng X et al., 2001). 
More recently, a link between the DMRT1 (doublesex and mab-3 related transcription factor 
1) tumor-suppressor protein and the deregulation of the GDNF signaling pathway has been 
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found in TGCTs. DMRT1 is a transcription factor implicated in testicular development. The 
loss of Dmrt1 in fetal testis induces the reduction of Ret expression and increased teratoma 
formation. However, increased DMRT1 expression is associated with increased GDNF 
signaling and spermatocytic seminoma (Krentz AD et al., 2009). Thus, it is possible to 
speculate that a reduced GDNF signaling, together with high expression of pluripotency 
genes, leads to somatic differentiation programs and teratoma insurgence. On the contrary, the 
postnatal overactivation of GDNF pathway may block differentiation of germ cell and 
spermatocytic tumor formation (Krentz et al., 2009).  
These observations suggest that a deregulation of the GDNF pathway might be implicated in 
germ cell carcinogenesis even if the molecular alterations involved are not known (Meng X et 
al., 2001).  
Apart from a single study (Viglietto G et al., 2000), there are scant informations on the 
expression of GDNF and its co-receptors in human TGCTs and their possible role in the 
pathogenesis remains to be completely established. 
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AIM OF THE PRESENT STUDY 
 
The neurotrophic factor GDNF has multiple functions involved in cell survival, proliferation 
and migration of different cell types. The experimental over-expression of GDNF in mouse 
testis leads to infertility and promotes seminomatous germ cell tumors in older animals. This 
observation suggests that although the underlying mechanisms are unknown, deregulation of 
the GDNF pathway may be implicated in germ cell carcinogenesis. However, apart from a 
single study (Viglietto G et al., 2000), little is known about the expression of GDNF and its 
co-receptors in human TGCTs. 
The aim of the present study is to determine the potential role of the GDNF pathway in the 
onset and progression of human seminoma germ cell tumors. For this purpose, we first 
analyzed the expression pattern of GFRA1 and Ret, the two major co-receptors for GDNF, in 
CIS and seminoma samples. We found that GFRA1 was expressed more extensively in CIS 
cells and invasive seminoma compared with normal testis.  
Therefore, to gain insights into the potential function of the activation of the GDNF pathway 
in seminoma cells we used the TCam-2 human seminoma cell line as an experimental model 
system.  
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MATERIAL AND METHODS 
 
5.1 Tumor samples  
Surgical samples were obtained from ten patients with testicular seminoma (mean age: 35.5 
years, range: 23-50 years). The specimens were fixed in 10% formalin-buffered solution and 
paraffin-embedded. Morphological analysis of hematoxylin-eosin stained sections indicated 
that tumor samples contained variable amounts of seminiferous tubules with qualitatively 
normal spermatogenesis (8/10), atrophic seminiferous tubules (8/10), seminiferous tubules 
with pre-invasive CIS cells (8/10) and invasive seminoma cells (10/10).  
 
5.2 Immunohistochemistry (IHC) 
Immunohistochemistry was performed as described (Muciaccia B et al., 2010). Briefly, 3 µm 
thick paraffin tissue sections were serially collected, treated for antigen retrieval and 
incubated with primary antibodies (1:20 anti-human monoclonal RET; 1:100 anti-human 
CD34, anti-human inhibin and anti-PLAP from Novocastra; 1:200 anti-human GFRα1 from 
R&D Systems; 1:400 anti-human CD117 from Dako). The sections were then processed using 
the avidin-biotin peroxidase complex (ABC) procedure, according to the manufacturer’s 
instructions (UltraTek HRP Anti-Polyvalent Kit, ScyTek Laboratories). Negative controls 
were performed by omitting the primary antibodies (data not shown). Peroxidase activity was 
revealed using 3,3-diaminobenzidine tetrahydrochloride (Roche), and the nuclei were 
counterstained using hematoxylin solution. For immunohistochemistry of the TCam-2 cells, 
the cells were harvested, collected by centrifugation, fixed in 4% paraformaldehyde at 4°C for 
10 min and paraffin-embedded. Paraffin sections, 5 µm thick, were processed as described 
above for tissue sections. Negative controls were performed by omitting the primary 
antibodies.  
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5.3 TCam-2 cell cultures  
The TCam-2 human cell line was derived in 1993 from a primary testicular tumor sample of 
pure classical seminoma (Mizuno Y et al., 1993). TCam-2 cell line is the only validated  
seminoma cell line (de Jong, J et al., 2008; Eckert D et al., 2007; Goddard NC et al., 2007; 
Mizuno Y et al., 1993).TCam-2 cells were cultured as described in RPMI 1640 (Lonza) 
supplemented with 10% fetal bovine serum (Lonza) and penicillin/streptomycin (Invitrogen) 
at 37°C in a humidified atmosphere with 5% carbon dioxide(Goddard NC et al., 2007). To 
test the effect of GDNF on cell proliferation, TCam-2 cells were maintained for 16 hours 
under serum-free conditions and then treated in the presence or absence of 100 ng/ml GDNF 
(R&D Systems) or 10% (v/v) fetal bovine serum. After 24, 48 and 72 hours, the cells were 
trypsinized, harvested and counted. Dead cells were evaluated using trypan blue exclusion 
staining. To test the effect of GDNF on cell cycle entry, the cells were maintained for 16 
hours under serum-free conditions and then cultured in the absence or in the presence of 100 
ng/ml GDNF or 10% fetal bovine serum as positive controls for 12, 24 and 48 hours. The 
cells were recovered and stained with a propidium iodide/RNase solution. The cell 
suspensions were analyzed with a Beckman Coulter Epics XL Flow Cytometer. To test for 
gelatinolytic activity, TCam-2 cell conditioned media were collected after 48 hours, and the 
cells were lysed in 0.5% Triton X-100 in 0.1 M Tris-HCl, pH 8.1 (Catizone A et al., 2010).  
 
5.4 Reverse transcription-PCR (RT-PCR) Analysis  
The cells were harvested and total RNA was extracted with a phenol-chloroform extraction 
(TRIreagent, Sigma-Aldrich). One microgram of total RNA per sample was used for cDNA 
synthesis with random hexamers and Transcriptor reverse transcriptase (Roche). In control 
samples, reverse transcriptase was omitted to monitor genomic DNA contaminations. PCR 
was performed in a volume of 25 µl containing 2 µl cDNA, 50 µM KCl, 10 mM Tris–HCl 
(pH 8.3), 1.5 mM MgCl, 50 pmol of each amplification primer, 200 mM dNTPs, and 0.5 U 
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Taq DNA polymerase (Roche). The primers and PCR details are described in Table 1. The 
PCR products were fractionated by 1.8 % agarose gel electrophoresis and visualized by 
ethidium bromide staining. Experiments were performed three times, using different RNA 
preparations. 
 
5.5 Boyden chamber assays 
The cells were assayed for their ability to migrate through a polycarbonate filter (pore size, 8 
µm; Whatman International) using Boyden chambers (NeuroProbe). The cells (5 X 104/well) 
were added to the upper chamber, and GDNF, anti-GDNF antibody (R&D Systems), 
CXCL12 (SDF-1 from Peproteck), isotype control antibody or FBS (control wells) were 
added alone or in combination in the lower chamber. To analyze the GDNF-triggered 
pathways, 10 µm U0126 (MEK inhibitor), 10 µm or 15 µm LY294002 (PI3K inhibitor), 10 
µm PP-2 (Src inhibitor) were added to both the upper and bottom chambers. The various 
concentration of inhibitors used did not affect cell viability as assessed by FACS analysis of 
propidium iodide stained cells (data not shown). The chambers were incubated for 5 hours at 
37°C. The cells were assayed for their ability to invade through filters (8 µm) coated with 
MatrigelTM Basement Membrane Matrix, Growth Factor Reduced (BD Biosciences) using 
Boyden chambers. The cells (5 X 104/well) were added to the upper chamber, and GDNF or 
CXCL12 were added to the lower chamber. To obtain pericellular protease inhibition, a 
cocktail of 250 µM E64, 2 µM leupeptin, 100 µM pepstatin A, 2.2 µM aprotinin and 50 µM 
GM6001, termed the protease inhibitor mix (prot. inh. mix) was prepared as previously 
described and added to both the upper and bottom chambers (Carragher NO et al., 2006). 
Invasion was allowed to proceed for 24 or 48 hours at 37°C in a humidified atmosphere with 
5% carbon dioxide, at which time filters were fixed and stained. The cells from the upper side 
of the filter were carefully removed using a cotton swab. The cells that had migrated or 
invaded to the lower side of the filters were quantified by bright-field microscopy using a 40x 
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objective, and the average number of cells per field was calculated. Data are expressed as a 
migration index and calculated as the fold increase over the control. The control cells were 
either in serum-free RPMI 1640 containing 0.1% BSA or in serum-free RPMI 1640 
containing 0.1% BSA and DMSO. The results are reported as the means ± standard error 
(SE).  
 
5.6 Gelatin zymography for metalloproteinases (MMPs) detection 
Gelatinolytic activity of the TCam-2 conditioned media and cell extracts were assayed as 
previously described (Catizone A et al., 2010). Briefly, 20 µl aliquots of conditioned media 
and cell extracts were fractionated by 10% SDS-polyacrylamide gel electrophoresis in the 
presence of 0.1% gelatin under non-reducing conditions. Following electrophoresis, the gels 
were washed twice in 2.5% Triton X-100 for 30 min at room temperature to remove SDS. The 
gels were incubated at 37°C overnight in substrate buffer, stained with 0.5% Coomassie 
Brilliant Blue R250 and destained in 30% methanol and 10% glacial acetic acid (vol/vol).  
 
5.7 Statistical Analysis 
All quantitative data are presented as the mean ± standard error of the mean (SEM). Data 
were analyzed for significant differences between different subsets of migrated or invading 
cells using a one-way analysis of variance (ANOVA) followed by a post hoc Dunnet test. The 
significance level was fixed at α=0.05. 
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RESULTS 
 
6.1 GFRA1 is extensively expressed in CIS and invasive seminoma cells  
Investigation of the expression patterns of GFRA1 and Ret was performed by IHC on ten 
different testicular seminoma samples (Figure 8, 9). Adjacent serial sections were stained with 
antibodies against c-Kit (CD117) and PLAP, two diagnostic markers routinely used to 
identify CIS and seminoma cells, and with anti-CD34 to detect endothelial cells (Figure 10). 
In seminiferous tubules displaying qualitative normal spermatogenesis near a CIS lesion, 
GFRA1 expression was detected, as previously described, in subsets of dark and pale type A 
spermatogonia (Grisanti L et al., 2009) and in interstitial Leydig cells (Davidoff MS et al., 
2001) (Figure 8). Compared with preserved testicular parenchyma, GFRA1 expression was 
expressed more extensively in both CIS and intratubular seminoma cells, while expression 
levels varied from moderate to strong in invasive seminoma cells (Figure 8). In preserved 
testicular parenchyma, Ret expression was not detected in seminiferous tubules, while it was 
clearly detected in interstitial tissue, possibly in the Leydig cell lineage (Figure 9). In some 
instances, a strong Ret expression was detected in Sertoli cells of atrophic seminiferous 
tubules, with a thickened peritubular wall and lack of germ cells, as well as in Sertoli cell 
cytoplasm of seminiferous tubules containing pre-invasive CIS cells. Finally, in invasive 
seminoma lesions, no Ret expression was detected in seminoma cells, while Ret-positive 
staining was detected in both endothelial cells (identified morphologically and by CD34 
staining) and in cell clusters, possibly endothelial/pericyte precursors, located in perivascular 
areas (Figure 9). 
 
6.2 The TCam-2 seminoma cell line expresses the co-receptors for GDNF 
Because CIS and seminoma cells highly express the GDNF co-receptor GFRA1, we tested the 
hypothesis that GDNF is involved in tumor germ cell proliferation. To this end, we took 
 Fig. 8 - Immunohistochemical detection of GFRA1 receptor in TGCTs.  
Images are from six representative seminoma tissue samples. GFRA1 cellular localization: (i) seminiferous 
tubules with preserved spermatogenesis adjacent to CIS lesion. GFRA1 expression was detected in Leydig cells 
(asterisks) and in the basal compartment of seminiferous tubules where subsets of dark and pale type A 
spermatogonia were positive (arrows); (ii) seminiferous tubules with CIS cells showing high GFRA1 staining 
(arrows). CIS cells were recognized morphologically or with anti-c-Kit immunodetection on serial sections (not 
shown); (iii) GFRA1-positive intratubular seminoma cells (asterisk). GFRA1 expression was up-regulated in 
seminoma cells compared with spermatogonia (arrows) in adjacent seminiferous tubules with preserved 
spermatogenesis (star); (iv) c-Kit (CD117) and (v) GFRA1 immunostaining in adjacent sections of the same 
seminoma tissue sample. Note the fibrous septa rich in infiltrating inflammatory cells (arrows); (vi) high 
magnification of GFRA1-positive invasive seminoma cells (arrows), infiltrating lymphocytes are negative 
(asterisks). 
 Fig. 9 - Immunohistochemical detection of Ret receptor in TGCTs.  
Images are from six representative seminoma tissue samples. Ret cellular localization: (i) lack of Ret staining in 
preserved testicular parenchyma of seminiferous tubules both in germ and somatic cells, while Ret-positive 
cells (possibly Leydig cells) are detected in the interstitial compartment (asterisk). Dark type A spermatogonia 
are indicated by arrows, and a Sertoli cell nucleus is indicated by an arrowhead; (ii) high Ret cytoplasmic 
staining was detected in Sertoli cells (stars) present in seminiferous tubules containing Ret-negative CIS cells 
(arrows); (iii) in some seminiferous tubules, clusters of Ret-positive Sertoli cells were found sloughing into the 
lumen (asterisk). Arrowhead points to a Ret-positive Sertoli cell properly arranged in the epithelium. Arrows 
indicate the same CIS cell identified on adjacent sections, which is Ret-negative and GFRA1-positive (inset). 
An asterisk indicates the same cluster of Sertoli cells shown in (iii); (iv) in invasive seminoma cells, no Ret 
expression was detected. Arrows point to fibrous septa containing Ret-positive cells; (v) Ret expression was 
detected in endothelial cells (arrows) lining the lumen of vessels. Endothelial cells show a morphological 
activated phenotype with large heterochromatic nuclei; and (vi) Ret staining was detected in clusters of possibly 
endothelial/pericyte precursors (arrows). Seminoma cells are Ret-negative (asterisks).  
 
 Fig. 10 - Immunohistochemical analysis performed on adjacent paraffin sections obtained from sample # 7.  
GFRA1 antibodies identify CIS and seminoma cells similar to two routinely used diagnostic markers, such as     
c-Kit antibodies (CD117) and PLAP. Anti-CD34 antibodies detect endothelial cells. 
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advantage of TCam-2 cells, currently, the only available validated seminoma cell line. First, 
expression of GDNF co-receptors was analyzed by RT-PCR analysis (Figure 11A) and by 
IHC (Figure 11B). GFRA1 is alternatively spliced into two highly homologous isoforms, 
GFRA1a and GFRA1b, which differ at five amino acids (Shefelbine SE et al., 1998). 
Recently GFRA1b, but not GFRA1a, has been demonstrated to be responsible of cell 
migration and invasion in C6 glioma cells (Wan G et al., 2010). Both GFRA1 isoforms are 
expressed in the TCam-2 cells (Figure 11A). Ret undergoes alternative splicing, which 
generates the Ret9 and Ret51 isoforms, differing at the carboxyl-termini (Arighi E et al., 
2005). As observed by RT-PCR analysis, both Ret9 and Ret51 transcripts are present in the 
TCam-2 cells (Figure 11A). In order to verify whether also GFRA1 and Ret receptor proteins 
were expressed, we performed IHC analysis on TCam-2 cells. GFRA1, but not RET, was 
detected by IHC (Figure 11B). We next addressed whether GDNF modulates TCam-2 
proliferation or survival. In fact, GDNF is a known key factor regulating spermatogonial stem 
cell self-renewal and proliferation (Hofmann MC et al., 2008). Serum-starved cells were 
treated in the absence and in the presence of 100 ng/ml GDNF with or without 10% FBS for 
24, 48 and 72 hours. The total number of cells, as well as the number of dead cells, did not 
vary in GDNF-treated cells compared with the control at each time-point analyzed (Figure 
12). In order to determine the percentage of TCam-2 cells in S phase FACS analysis, using 
the same treatment conditions for 12, 24 and 48 hours, was performed (Figure 13). While FBS 
significantly increased the percentage of cells in S phase compared with the control, GDNF 
did not induce S-phase entry of TCam-2 cells at any time point analyzed (Figure 13).  
 
6.3 GDNF induces TCam-2 cell migration  
Intriguingly, in other cellular systems, GDNF has been implicated in the directed migration 
and invasion of normal and tumor cells (Okada Y et al., 1999; Paratcha G et al., 2006; Song H 
and Moon A, 2006; Su CM et al., 2009; Tang MJ et al., 1998; Veit C et al., 2004; Young HM 
 
 
 
 
 
Fig. 11 - Identification of GDNF co-receptor variants expressed in TCam-2 cells.  
(A) RT-PCR analysis. Total RNA was prepared from TCam-2 cells and used as a template for RT-PCR analysis. A 
sample containing RNA from human brain and a sample containing no RNA (not shown) were used as controls. A β-
actin primer set was used as a loading control. (B) Immunohistochemical detection of GDNF co-receptors in TCam-2 
cells: (i) GFRA1 and (ii) Ret. No staining is present by omitting the primary antibodies (inset). 
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Fig. 12 - GDNF is not a mitogenic factor for TCam-2 cells.
(A) TCam-2 cells were serum-starved for 16 hours and then cultured in the presence or absence of 100 ng/ml 
GDNF with or without 10% FBS for 24, 48 and 72 hours. Percentage of dead cells at each time point is shown 
in (B). The results are from a representative of three experiments performed. Data are shown as the 
mean±SEM of triplicate samples.
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Fig. 13 - GDNF does not induce S-phase entry in TCam-2 cells. 
(A) Flow cytometry analysis reveals that TCam-2 cells have a tetraploid DNA content. LYMPHO: human 
lymphocytes. (B) Cell cycle phase distribution of TCam-2 cells treated in the absence or presence of 100 ng/ml 
GDNF or with 10 % FBS (as a positive control) for 12, 24 and 48 hours of culture. Percentage of cells in G1, G2 and 
S phase for each experimental condition is presented in (C). The results are from a representative of three 
experiments performed. *p<0.05 (one-way Anova, Dunnet post hoc) 
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et al., 2001). More interestingly, we recently found that in vitro GDNF is a chemoattractant 
for murine undifferentiated spermatogonia (Dovere L, manuscript in preparation). Based on 
these observations, we hypothesized that TCam-2 cells may migrate in response to a GDNF 
gradient. Thus, in order to test whether the GDNF pathway could be involved in TCam-2 
seminoma cell migration we performed Boyden chamber migration assays with increasing 
concentrations of GDNF (20 to 150 ng/ml). Therefore to create a positive gradient for the 
putative chemoattractant, the upper compartment was filled with DMEM+0,1% BSA alone, 
while the lower chamber contained DMEM+0,1% BSA plus GDNF. The results showed that, 
consistent with our hypothesis, after 5h of incubation, a significant effect on cell migration 
was achieved with 100 ng/ml and 150 ng/ml GDNF (Figure 14A). As a control, we tested if 
the anti-GDNF antibody was able to block this effect. Addition of the blocking antibody, 
along with GDNF, completely neutralized the GDNF activity on TCam-2 cells, reducing cell 
migration at a level comparable to the control (Figure 14B) No effect was observed after 
administration of the antibody isotype control (Figure 14B). When GDNF was added to both 
the upper and lower chambers, and therefore no chemokine gradient was present in the 
Boyden chamber, cell migration was decreased to the control level (Figure 14B). 
Chemoattractant activity of 1% FBS was comparable with 100 ng/ml GDNF, and no synergic 
effect was found when the TCam-2 cells were stimulated with both 1% FBS and 100 ng/ml 
GDNF (Figure 14B). 
Recently the small cytokine CXCL12, a known chemoattractant for different cell types, has 
been reported to be able to induce invasive migration on TCam-2 seminoma cells by 
activation of the ERK pathway (Gilbert Dc et al., 2009). By comparing the GDNF 
chemoattractant activity with that of CXCL12, we found that GDNF is more effective 
(approximately 50%) than CXCL12 (Figure 14C). In conclusion, these data show for the first 
time, that GDNF can stimulate directional migration of TCam-2 seminoma cell line. 
Intriguingly, along with the observation that GDNF is an in vitro chemoattractant for 
 Fig. 14 - GDNF-dependent migration of TCam-2 cells.  
Cell migration was evaluated using the Boyden chamber assay as detailed in the Materials and Methods section. (A) 
TCam-2 cells were treated with increasing concentrations of GDNF. (B) TCam-2 cells were treated as indicated at final 
concentrations of 100 ng/ml GDNF, 15 µg/ml anti-GDNF antibody, 15 µg/ml control-IgG or fetal bovine serum (FBS) 
(1% v/v). To abrogate the GDNF gradient in the Boyden chamber, 100 ng/ml GDNF was added both in the upper and 
lower chamber. (C) TCam-2 cells were treated with 100 ng/ml GDNF or with increasing concentrations of CXCL12 
(SDF-1). Data are expressed as the mean ± SEM (n=3, measured in triplicate). *P<0.001 vs. control (one-way Anova, 
Dunnet post hoc).  
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undifferentiated mouse spermatogonia (Dovere L, manuscript in preparation), these data 
suggest that the chemoattractant activity of GDNF is conserved in both normal and 
transformed germ cells. We next investigated the GDNF-triggered pathway involved in 
TCam-2 migration. In different tumor cell types, GDNF activates the MEK and PI3K 
pathways (Su CM et al., 2009; Song H and Moon A, 2006; Veit C et al., 2004). Three 
different inhibitors were tested as follows: PP-2 (a potent Src-inhibitor), LY294002 (a PI3K-
inhibitor), and U0126 (a MEK-inhibitor). PP-2 (Figure 15A) and UO126 (Figure 15B), but 
not LY294002 (Figure 15C), completely abolished GDNF-induced cell migration. These data 
suggest that GDNF-induced migration is mediated by the Src and MEK pathways but not by 
the PI3K pathway. 
 
6.4 GDNF promotes TCam-2 cell invasion in a protease-dependent fashion 
We next addressed whether invasion could be triggered by GDNF in TCam-2 cells. For this 
purpose we performed modified Boyden chamber assays with Matrigel-coated filters. 
Matrigel is a solubilized basement membrane preparation whose major component is laminin, 
followed by collagen IV, heparan sulfate proteoglycan, and entactin. This substrate is useful 
to mimic the in vivo mechanisms on the base of tissue invasion where cells have to move 
trough and degrade the ECM components to invade adjacent tissues. Invasion was analyzed at 
two time points: 24 and 48 hours. At both time points, GDNF administration significantly 
enhanced cell invasion compared with the control, as well as with CXCL12 (Figure 16A). 
Tumor cell invasion can occur through two modalities: a proteolytic mesenchymal-like or 
non-proteolytic amoeboid-like modality (Sahai E and Marshall CJ, 2003; Wolf K et al., 
2003). The mesenchymal-like strategy of invasion requires extracellular matrix degradation 
by proteases, including matrix metalloproteinases (MMPs), and thus, it is sensitive to protease 
inhibitors. In contrast, the amoeboid-type modality is protease-independent, with cells that 
adopt a rounded morphology. To identify which of the two modalities is employed by the 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15 - The effect of different inhibitors on GDNF-induced TCam-2 cell migration.  
Cell migration was evaluated using the Boyden chamber assay as detailed in the Materials and Methods section. TCam-
2 cells were pre-treated for 30 min with 10 µm PP-2 (A), 10 µm U0126 (B) or an indicated concentration of LY294002 
(C) followed by stimulation with 100 ng/ml GDNF. In the control samples, DMSO was added to the highest 
concentration present in the treated samples. The results are expressed as the mean ± SEM, (n=3, measured in 
triplicate). *P<0.001 vs. control (one-way Anova, Dunnet post-hoc).  
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 Fig. 16 - GDNF promotes invasion in TCam-2 cells.  
Matrigel invasion assays were performed and evaluated as detailed in the Materials and Methods section. (A) TCam-2 
cells were treated for 24 and 48 hours with 100 ng/ml GDNF and 100 ng/ml CXCL12; (B) TCam-2 cells were pre-
treated for 30 min with indicated protease inhibitors followed by stimulation with GDNF (100 ng/ml). The results are 
expressed as the mean ± SEM (n=2, measured in triplicate). * p<0.05, **p<0.001 (one-way Anova, Dunnet post-hoc). 
(c) MMP-2 and MMP-9 gelatinase activity in TCam-2 conditioned media and cell extracts. Images are representative of 
three independent experiments.  
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TCam-2 cells in GDNF-induced cell invasion, we tested a cocktail of protease inhibitors 
(named prot. inh. mix), which included GM6001 (a broad matrix metalloproteinases 
inhibitor), E64 (targets cysteine proteases such as cathepsins B, L, H and K), pepstatin A 
(inhibits aspartic proteases including cathepsin D), leupeptin (a broad inhibitor of cysteine 
proteases and cathepsin D) and aprotinin (an inhibitor of serine proteases, such as urokinase 
and tissue plasminogen activator) (Carragher et al. 2006). Prot. inh. mix administration 
completely abolished the GDNF-induced TCam-2 cell invasion (Figure 16B), suggesting a 
protease-dependent invasion strategy. To evaluate the contribution of MMPs to TCam-2 cell 
invasion, the MMPs-specific inhibitor GM6001 was tested alone, and its activity was 
compared with prot. inh. mix without GM6001. GM6001 alone, but not the other inhibitors, 
reduced the GDNF-induced TCam-2 cells invasion, suggesting the involvement of MMPs 
(Figure 16B). MMP-2 and MMP-9 activity (Figure 16C) was detected in TCam-2 cell extracts 
and conditioned medium by gelatin zymography.  
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DISCUSSION 
 
In recent years, a large body of evidence pointed to the importance of GDNF for proper 
spermatogenesis. In mice, GDNF is secreted by Sertoli cells and promotes spermatogonial 
stem cell self-renewal (Hofmann MC, 2008). Over-expression of GDNF in adult transgenic 
mice induces proliferation of clusters of undifferentiated spermatogonia within seminiferous 
tubules (Meng X et al., 2001). Additionally, older animals develop testicular tumors that 
mimic human seminoma, suggesting that over-activation of this pathway may lead to the 
insurgence of TGCTs (Meng X et al., 2001). Supporting this hypothesis, Ret, a co-receptor 
for GDNF, is a well-known oncogene that upon mutation and/or rearrangement undergoes 
constitutive GDNF- and GFRA1-independent activation. Activating mutations of Ret were 
previously reported in several types of cancer, including thyroid, pituitary, adrenal and 
melanoma cancer. However, human seminoma does not appear to be linked to mutations or 
relevant polymorphisms of Ret (Chevalier N et al., 2010). An alternative mechanism for 
driving germ cell tumor progression could be the up-regulation of wild-type GFRA1 and/or 
Ret proteins. Overexpression of GFRA1 and/or Ret has been found in different cancers 
(Dawson DM et al., 1998; Nakashima M et al., 2007; Takaya K et al., 1996), and in some 
instances, Ret over-expression correlates with poor survival (Ito Y et al., 2005) as well as the 
development of a subgroup of breast tumors (Esseghir S et al., 2007). We demonstrate, for the 
first time, that GFRA1 is extensively expressed in CIS, and its expression is maintained in 
invasive seminoma. However, Ret was not detected by immunohistochemistry in normal 
germ cells, in CIS cells, or in the invasive seminoma. In TCam-2 cells, Ret was detected at 
mRNA but not protein levels, suggesting that in CIS and seminoma cells, Ret protein may be 
expressed at very low levels. Alternatively, GFRA1 may transduce GDNF signal in a Ret-
independent fashion. To date, a number of CIS and seminoma cells markers are known to be 
expressed in fetal gonocytes but not in adult spermatogonia. However, CIS cells also express 
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genes found in the germ cells of normal adult testis (i.e., VASA, TSPY, DAZ and DAZL) 
(Rajpert-De ME, 2006). Because GFRA1 is detected in dark and pale type A spermatogonia, 
GFRA1 lengthens the list of tumor germ cell markers that are expressed in normal germ cells. 
To elucidate the biological activity of GDNF in TGCTs, we employed the TCam-2 cell line as 
an experimental model system. Even though TCam-2 cells express the GDNF co-receptors, 
GDNF did not affect cell survival and proliferation. Because GDNF acts as a chemoattractant 
in several normal and tumor cell types (Okada Y et al. 1999; Paratcha G et al. 2006; Song H 
and Moon A, 2006; Su CM et al., 2009; Tang MJ et al., 1998; Veit C et al., 2004; Young HM 
et al., 2001), we tested the hypothesis that GDNF is a chemoattractant for the TCam-2 
seminoma cell line. GDNF induced TCam-2 cell migration and was mediated by the Src and 
MEK pathways. In contrast, PI3K does not seem to be involved in GDNF-induced migration. 
Our findings are consistent with the observation that in some pancreatic carcinoma cells, 
GDNF is not mitogenic but acts as a chemoattractant (Veit C et al., 2004). We found that 
GDNF induces TCam-2 cell invasion through GFR-Matrigel, a matrix consisting of laminin, 
collagen, entactin and growth factors. Invasive tumor dissemination involves proteolytic 
degradation and remodeling of the extracellular matrix (ECM) barriers, a process dependent 
upon extracellular proteases, including MMPs (Coussens LM et al., 2002). However, protease 
inhibition does not completely abolish tumor cell migration and dissemination, suggesting 
alternative compensating protease-independent mechanisms (Coussens LM et al., 2002; 
Zucker S et al., 2000). Of note, when proteolysis is blocked, some tumor cell types switch 
from a protease-dependent mesenchymal type of motility to an ameboid-like rounded mode of 
motility that requires Rho/ROCK signaling (Sahai E and Marshall CJ, 2003; Wolf K et al., 
2003). By using inhibitors of a wide range of pericellular proteases, we found that the 
invasive strategy used by TCam-2 cells is protease-dependent, which suggests a 
mesenchymal-like invasion. Among candidate proteases implicated in GDNF-induced TCam-
2 cell invasion are the MMPs, the most prominent family of proteases involved in 
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tumorigenesis (Kessenbrock K et al., 2010). The lack of invasion upon inhibition of 
pericellular proteases suggests that TCam-2 cells are not able to undergo the mesenchymal-
ameboid switch, thus suggesting a lack of plasticity compared with more aggressive tumor 
cell types (Carragher NO et al., 2006). 
We demonstrated that GFRA1 expression is upregulated in CIS and seminoma cells. This 
raises the question as to the source of GDNF in seminoma. In normal human testis, GDNF is 
produced by the Sertoli and peritubular cells, which form the wall of the seminiferous tubules 
(Spinnler K et al,. 2010). The expression level of GDNF was found to be similar in 
peritubular cells isolated from patients suffering from azoospermia and fibrotic remodeling of 
the peritubular wall (Spinnler K et al., 2010). At present, data are not available regarding the 
expression level and regulation of GDNF in normal human testis or those affected by 
pathological conditions, including TGCTs. In infertile mouse models, GDNF levels are 
inversely correlated with the germ cell content of the testis, possibly through the regulation of 
the hypothalamus–pituitary axis (Tadokoro Y et al., 2002). Moreover, GDNF expression in 
Sertoli cells is induced by inflammatory cytokines (Simon L et al., 2007). Therefore, it could 
be speculated that, as described in some breast cancers (Esseghir S et al., 2007), local  levels 
of GDNF in the tumor microenvironment may be increased as a consequence of leukocyte 
infiltration and/or spermatogenic arrest, which are commonly found in TGCTs. Although 
currently it is not possible to directly address whether CIS and intratubular seminoma cells 
respond to local GDNF by increasing their ability to migrate and invade the interstitial 
compartment, our combined in vivo and in vitro observations suggests that GDNF may induce 
tumor cell migration and dissemination within the testis. Recently, it has been suggested that 
the expression level of the chemokine CXCL12 (SDF-1) in TGCT samples is a predictive 
marker of relapse for patients affected by a subset of type II TGCTs, i.e., stage I non-
seminoma (NS). Patients with moderate to strong expression of CXCL12 have a reduced risk 
of relapse, suggesting that a high level of chemokines in the tumor microenvironment may 
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impact tumor germ cell spreading and metastatic potential (Gilbert DC et al., 2009). 
Following this line of reasoning, it would be interesting to assess whether the expression level 
of GDNF signaling pathway molecules have a similar prognostic value in patients affected by 
seminoma tumors. 
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